Jeff Borghoff and his wife Kimberly speak about participating in the Biogen drug trial testing aducanumab, a drug that targets beta-amyloid. The late-stage trial was recently canceled, news that sent participants, their families, researchers and stocks reeling.
If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.